Clinical characteristics, predictors of immune reconstitution inflammatory syndrome and long-term prognosis in patients with Kaposi sarcoma.
Identifieur interne : 000430 ( PubMed/Checkpoint ); précédent : 000429; suivant : 000431Clinical characteristics, predictors of immune reconstitution inflammatory syndrome and long-term prognosis in patients with Kaposi sarcoma.
Auteurs : Patricia Volkow [Mexique] ; Gabriela Cesarman-Maus [Mexique] ; Pamela Garciadiego-Fossas [Mexique] ; Enrique Rojas-Marin [Mexique] ; Patricia Cornejo-Juárez [Mexique]Source :
- AIDS research and therapy [ 1742-6405 ] ; 2017.
Abstract
To investigate the predictive factors for the development of Kaposi sarcoma-related immune reconstitution inflammatory syndrome (KS-IRIS) and long-term prognosis in patients starting combined antiretroviral therapy (cART).
DOI: 10.1186/s12981-017-0156-9
PubMed: 28558783
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:28558783Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clinical characteristics, predictors of immune reconstitution inflammatory syndrome and long-term prognosis in patients with Kaposi sarcoma.</title><author><name sortKey="Volkow, Patricia" sort="Volkow, Patricia" uniqKey="Volkow P" first="Patricia" last="Volkow">Patricia Volkow</name><affiliation wicri:level="1"><nlm:affiliation>Infectious Diseases Department, Instituto Nacional de Cancerología (INCan), Av. San Fernando No. 22, Col. Sección XVI, Deleg. Tlalpan, 14080, Mexico City, Mexico. pvolkowf@gmail.com.</nlm:affiliation><country xml:lang="fr">Mexique</country><wicri:regionArea>Infectious Diseases Department, Instituto Nacional de Cancerología (INCan), Av. San Fernando No. 22, Col. Sección XVI, Deleg. Tlalpan, 14080, Mexico City</wicri:regionArea><wicri:noRegion>Mexico City</wicri:noRegion></affiliation></author><author><name sortKey="Cesarman Maus, Gabriela" sort="Cesarman Maus, Gabriela" uniqKey="Cesarman Maus G" first="Gabriela" last="Cesarman-Maus">Gabriela Cesarman-Maus</name><affiliation wicri:level="1"><nlm:affiliation>Hematology Department, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.</nlm:affiliation><country xml:lang="fr">Mexique</country><wicri:regionArea>Hematology Department, Instituto Nacional de Cancerología (INCan), Mexico City</wicri:regionArea><wicri:noRegion>Mexico City</wicri:noRegion></affiliation></author><author><name sortKey="Garciadiego Fossas, Pamela" sort="Garciadiego Fossas, Pamela" uniqKey="Garciadiego Fossas P" first="Pamela" last="Garciadiego-Fossas">Pamela Garciadiego-Fossas</name><affiliation wicri:level="1"><nlm:affiliation>Infectious Diseases Department, Instituto Nacional de Cancerología (INCan), Av. San Fernando No. 22, Col. Sección XVI, Deleg. Tlalpan, 14080, Mexico City, Mexico.</nlm:affiliation><country xml:lang="fr">Mexique</country><wicri:regionArea>Infectious Diseases Department, Instituto Nacional de Cancerología (INCan), Av. San Fernando No. 22, Col. Sección XVI, Deleg. Tlalpan, 14080, Mexico City</wicri:regionArea><wicri:noRegion>Mexico City</wicri:noRegion></affiliation></author><author><name sortKey="Rojas Marin, Enrique" sort="Rojas Marin, Enrique" uniqKey="Rojas Marin E" first="Enrique" last="Rojas-Marin">Enrique Rojas-Marin</name><affiliation wicri:level="1"><nlm:affiliation>Radiology Department, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.</nlm:affiliation><country xml:lang="fr">Mexique</country><wicri:regionArea>Radiology Department, Instituto Nacional de Cancerología (INCan), Mexico City</wicri:regionArea><wicri:noRegion>Mexico City</wicri:noRegion></affiliation></author><author><name sortKey="Cornejo Juarez, Patricia" sort="Cornejo Juarez, Patricia" uniqKey="Cornejo Juarez P" first="Patricia" last="Cornejo-Juárez">Patricia Cornejo-Juárez</name><affiliation wicri:level="1"><nlm:affiliation>Infectious Diseases Department, Instituto Nacional de Cancerología (INCan), Av. San Fernando No. 22, Col. Sección XVI, Deleg. Tlalpan, 14080, Mexico City, Mexico.</nlm:affiliation><country xml:lang="fr">Mexique</country><wicri:regionArea>Infectious Diseases Department, Instituto Nacional de Cancerología (INCan), Av. San Fernando No. 22, Col. Sección XVI, Deleg. Tlalpan, 14080, Mexico City</wicri:regionArea><wicri:noRegion>Mexico City</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28558783</idno><idno type="pmid">28558783</idno><idno type="doi">10.1186/s12981-017-0156-9</idno><idno type="wicri:Area/PubMed/Corpus">000175</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000175</idno><idno type="wicri:Area/PubMed/Curation">000175</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000175</idno><idno type="wicri:Area/PubMed/Checkpoint">000175</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000175</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Clinical characteristics, predictors of immune reconstitution inflammatory syndrome and long-term prognosis in patients with Kaposi sarcoma.</title><author><name sortKey="Volkow, Patricia" sort="Volkow, Patricia" uniqKey="Volkow P" first="Patricia" last="Volkow">Patricia Volkow</name><affiliation wicri:level="1"><nlm:affiliation>Infectious Diseases Department, Instituto Nacional de Cancerología (INCan), Av. San Fernando No. 22, Col. Sección XVI, Deleg. Tlalpan, 14080, Mexico City, Mexico. pvolkowf@gmail.com.</nlm:affiliation><country xml:lang="fr">Mexique</country><wicri:regionArea>Infectious Diseases Department, Instituto Nacional de Cancerología (INCan), Av. San Fernando No. 22, Col. Sección XVI, Deleg. Tlalpan, 14080, Mexico City</wicri:regionArea><wicri:noRegion>Mexico City</wicri:noRegion></affiliation></author><author><name sortKey="Cesarman Maus, Gabriela" sort="Cesarman Maus, Gabriela" uniqKey="Cesarman Maus G" first="Gabriela" last="Cesarman-Maus">Gabriela Cesarman-Maus</name><affiliation wicri:level="1"><nlm:affiliation>Hematology Department, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.</nlm:affiliation><country xml:lang="fr">Mexique</country><wicri:regionArea>Hematology Department, Instituto Nacional de Cancerología (INCan), Mexico City</wicri:regionArea><wicri:noRegion>Mexico City</wicri:noRegion></affiliation></author><author><name sortKey="Garciadiego Fossas, Pamela" sort="Garciadiego Fossas, Pamela" uniqKey="Garciadiego Fossas P" first="Pamela" last="Garciadiego-Fossas">Pamela Garciadiego-Fossas</name><affiliation wicri:level="1"><nlm:affiliation>Infectious Diseases Department, Instituto Nacional de Cancerología (INCan), Av. San Fernando No. 22, Col. Sección XVI, Deleg. Tlalpan, 14080, Mexico City, Mexico.</nlm:affiliation><country xml:lang="fr">Mexique</country><wicri:regionArea>Infectious Diseases Department, Instituto Nacional de Cancerología (INCan), Av. San Fernando No. 22, Col. Sección XVI, Deleg. Tlalpan, 14080, Mexico City</wicri:regionArea><wicri:noRegion>Mexico City</wicri:noRegion></affiliation></author><author><name sortKey="Rojas Marin, Enrique" sort="Rojas Marin, Enrique" uniqKey="Rojas Marin E" first="Enrique" last="Rojas-Marin">Enrique Rojas-Marin</name><affiliation wicri:level="1"><nlm:affiliation>Radiology Department, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.</nlm:affiliation><country xml:lang="fr">Mexique</country><wicri:regionArea>Radiology Department, Instituto Nacional de Cancerología (INCan), Mexico City</wicri:regionArea><wicri:noRegion>Mexico City</wicri:noRegion></affiliation></author><author><name sortKey="Cornejo Juarez, Patricia" sort="Cornejo Juarez, Patricia" uniqKey="Cornejo Juarez P" first="Patricia" last="Cornejo-Juárez">Patricia Cornejo-Juárez</name><affiliation wicri:level="1"><nlm:affiliation>Infectious Diseases Department, Instituto Nacional de Cancerología (INCan), Av. San Fernando No. 22, Col. Sección XVI, Deleg. Tlalpan, 14080, Mexico City, Mexico.</nlm:affiliation><country xml:lang="fr">Mexique</country><wicri:regionArea>Infectious Diseases Department, Instituto Nacional de Cancerología (INCan), Av. San Fernando No. 22, Col. Sección XVI, Deleg. Tlalpan, 14080, Mexico City</wicri:regionArea><wicri:noRegion>Mexico City</wicri:noRegion></affiliation></author></analytic><series><title level="j">AIDS research and therapy</title><idno type="eISSN">1742-6405</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To investigate the predictive factors for the development of Kaposi sarcoma-related immune reconstitution inflammatory syndrome (KS-IRIS) and long-term prognosis in patients starting combined antiretroviral therapy (cART).</div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">28558783</PMID><DateCreated><Year>2017</Year><Month>05</Month><Day>31</Day></DateCreated><DateRevised><Year>2017</Year><Month>06</Month><Day>04</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1742-6405</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>May</Month><Day>30</Day></PubDate></JournalIssue><Title>AIDS research and therapy</Title><ISOAbbreviation>AIDS Res Ther</ISOAbbreviation></Journal><ArticleTitle>Clinical characteristics, predictors of immune reconstitution inflammatory syndrome and long-term prognosis in patients with Kaposi sarcoma.</ArticleTitle><Pagination><MedlinePgn>30</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12981-017-0156-9</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the predictive factors for the development of Kaposi sarcoma-related immune reconstitution inflammatory syndrome (KS-IRIS) and long-term prognosis in patients starting combined antiretroviral therapy (cART).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We studied a retrospective-cohort of consecutive antiretroviral-naïve patients with KS initiating cART from January 2005 to December 2011 and followed through June 2013. KS-IRIS was defined as ≥2 of the following: abrupt increase in number of KS lesions, appearance or exacerbation of lung-opacities or lymphedema, concomitantly with an increase in CD4+ cell-count ≥50 cells/mm(3) and a decrease of >1 log in viral-load once started cART. We compared individuals who met KS-IRIS criteria with those that did not and described the long-term follow-up.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We included 89 patients, 88 males; 35 (39%) developed KS-IRIS at a median of 10 weeks (IQR 4-16). KS-IRIS patients had more pulmonary-involvement (60% vs. 16.6% of patients; p < 0.0001), eight died attributed to pulmonary-KS. Thrombocytopenia <100,000/mm(3) at follow-up occurred in 36% of KS-IRIS vs. 4% in non-KS-IRIS patients (p = 0.0002), 45% KS-IRIS patients with thrombocytopenia died, non without KS-IRIS. Chemotherapy (bleomicyn-vincristine) was more frequently prescribed in KS-IRIS patients (88.6% vs. 29.6%) with no differences in outcome; 80% of all patients achieve KS complete remission, 52% of them never received chemotherapy. No difference between groups in the long-term follow-up (mean 52.4 ± 27.4 months) was found, only one patient developed a secondary malignancy (1.12%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Lung-involvement was predictive of IRIS development. Thrombocytopenia in KS-IRIS patients at week 12 follow-up after cART initiation was associated with high mortality. Over a third of patients with KS achieve remission without chemotherapy. Individuals that survive the initial period of KS-IRIS adhere to cART had a good long-term prognosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Volkow</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-1991-0923</Identifier><AffiliationInfo><Affiliation>Infectious Diseases Department, Instituto Nacional de Cancerología (INCan), Av. San Fernando No. 22, Col. Sección XVI, Deleg. Tlalpan, 14080, Mexico City, Mexico. pvolkowf@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cesarman-Maus</LastName><ForeName>Gabriela</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Hematology Department, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garciadiego-Fossas</LastName><ForeName>Pamela</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Infectious Diseases Department, Instituto Nacional de Cancerología (INCan), Av. San Fernando No. 22, Col. Sección XVI, Deleg. Tlalpan, 14080, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rojas-Marin</LastName><ForeName>Enrique</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Radiology Department, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cornejo-Juárez</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Infectious Diseases Department, Instituto Nacional de Cancerología (INCan), Av. San Fernando No. 22, Col. Sección XVI, Deleg. Tlalpan, 14080, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>05</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>AIDS Res Ther</MedlineTA><NlmUniqueID>101237921</NlmUniqueID><ISSNLinking>1742-6405</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Infect Agent Cancer. 2008 Jan 21;3:1</RefSource><PMID Version="1">18208585</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2007 Mar 30;21(6):775</RefSource><PMID Version="1">17413703</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS Res Ther. 2007 May 08;4:9</RefSource><PMID Version="1">17488505</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Opin Infect Dis. 2006 Feb;19(1):20-5</RefSource><PMID Version="1">16374213</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Oncologist. 2007 Jan;12(1):114-23</RefSource><PMID Version="1">17227906</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA. 1999 Dec 15;282(23):2220-6</RefSource><PMID Version="1">10605973</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2010 Apr;53(5):589-97</RefSource><PMID Version="1">19801945</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2004 Aug 20;18(12):1615-27</RefSource><PMID Version="1">15280772</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 1988 Oct 21;242(4877):426-30</RefSource><PMID Version="1">3262925</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2014 Sep 24;28(15):2327-9</RefSource><PMID Version="1">25313589</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 1992 Oct;6(10):1175-80</RefSource><PMID Version="1">1281643</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 2002 Jul 1;95(1):147-54</RefSource><PMID Version="1">12115328</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 1996 Sep;10(10):1101-5</RefSource><PMID Version="1">8874626</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2008 Jun 1;46(11):1694-701</RefSource><PMID Version="1">18433339</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 1989 Jan 13;243(4888):223-6</RefSource><PMID Version="1">2643161</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Medicine (Baltimore). 2002 May;81(3):213-27</RefSource><PMID Version="1">11997718</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 1998 Mar 26;338(13):853-60</RefSource><PMID Version="1">9516219</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2009 Aug 24;23(13):1701-6</RefSource><PMID Version="1">19550283</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2002 Jun 1;30(2):257-8</RefSource><PMID Version="1">12045689</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2008 Aug 1;47(3):410-7</RefSource><PMID Version="1">18582203</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Opin Infect Dis. 2011 Aug;24(4):295-301</RefSource><PMID Version="1">21666458</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2005 Mar 4;19(4):399-406</RefSource><PMID Version="1">15750393</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2008 May 11;22(8):937-45</RefSource><PMID Version="1">18453853</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Int Assoc Physicians AIDS Care (Chic). 2009 Mar-Apr;8(2):122-7</RefSource><PMID Version="1">19258527</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2007 Jun 19;21(10):1245-52</RefSource><PMID Version="1">17545700</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2002 Jan 15;34(2):224-33</RefSource><PMID Version="1">11740712</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 1994 Dec 16;266(5192):1865-9</RefSource><PMID Version="1">7997879</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 2004 Jun 15;100(12):2644-54</RefSource><PMID Version="1">15197808</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2013 Jun 05;8(6):e64392</RefSource><PMID Version="1">23755122</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Infect Dis. 2005 Jun;5(6):361-73</RefSource><PMID Version="1">15919622</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 1996 Jun;173(6):1477-80</RefSource><PMID Version="1">8648224</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2008 Mar 12;22(5):601-10</RefSource><PMID Version="1">18317001</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 1997 Sep;15(9):3085-92</RefSource><PMID Version="1">9294471</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2006 Feb 1;42(3):418-27</RefSource><PMID Version="1">16392092</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Infect Dis. 2002 May;2(5):281-92</RefSource><PMID Version="1">12062994</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst. 2002 Aug 21;94(16):1204-10</RefSource><PMID Version="1">12189223</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2001 Sep 15;19(18):3848-51</RefSource><PMID Version="1">11559722</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2004 Dec 15;39(12):1852-5</RefSource><PMID Version="1">15578411</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2013 Jun 19;27(10 ):1603-13</RefSource><PMID Version="1">23462220</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J STD AIDS. 2005 Jan;16(1):80-3</RefSource><PMID Version="1">15705280</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2007 Apr 23;21(7):875-7</RefSource><PMID Version="1">17415046</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2008 Mar 12;22(5):663-5</RefSource><PMID Version="1">18317012</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2005 Aug 1;23(22):5224-8</RefSource><PMID Version="1">16051964</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Pathol. 1995 Mar;146(3):727-34</RefSource><PMID Version="1">7887453</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 1989 Jun;7(6):774-80</RefSource><PMID Version="1">2565954</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 1998 Jan 24;351(9098):252-5</RefSource><PMID Version="1">9457095</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2000 Jun;30(6):882-92</RefSource><PMID Version="1">10880300</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Cancer. 2002 Apr 20;98(6):916-22</RefSource><PMID Version="1">11948473</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antimicrob Agents Chemother. 1997 Dec;41(12):2754-6</RefSource><PMID Version="1">9420052</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>HIV Med. 2006 Jul;7(5):291-3</RefSource><PMID Version="1">16945073</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Med. 1987 Feb;82(2):313-7</RefSource><PMID Version="1">3812527</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS Patient Care STDS. 2005 Oct;19(10):635-44</RefSource><PMID Version="1">16232048</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Aust N Z J Med. 1998 Dec;28(6):777-83</RefSource><PMID Version="1">9972406</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 1997 Dec;11(15):1895-6</RefSource><PMID Version="1">9412716</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Combined antiretroviral therapy</Keyword><Keyword MajorTopicYN="N">Highly active antiretroviral therapy</Keyword><Keyword MajorTopicYN="N">Immune reconstitution inflammatory syndrome</Keyword><Keyword MajorTopicYN="N">Kaposi sarcoma</Keyword><Keyword MajorTopicYN="N">Pulmonary Kaposi sarcoma</Keyword><Keyword MajorTopicYN="N">Thrombocytopenia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>03</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>05</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28558783</ArticleId><ArticleId IdType="doi">10.1186/s12981-017-0156-9</ArticleId><ArticleId IdType="pii">10.1186/s12981-017-0156-9</ArticleId><ArticleId IdType="pmc">PMC5450046</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Mexique</li></country></list><tree><country name="Mexique"><noRegion><name sortKey="Volkow, Patricia" sort="Volkow, Patricia" uniqKey="Volkow P" first="Patricia" last="Volkow">Patricia Volkow</name></noRegion><name sortKey="Cesarman Maus, Gabriela" sort="Cesarman Maus, Gabriela" uniqKey="Cesarman Maus G" first="Gabriela" last="Cesarman-Maus">Gabriela Cesarman-Maus</name><name sortKey="Cornejo Juarez, Patricia" sort="Cornejo Juarez, Patricia" uniqKey="Cornejo Juarez P" first="Patricia" last="Cornejo-Juárez">Patricia Cornejo-Juárez</name><name sortKey="Garciadiego Fossas, Pamela" sort="Garciadiego Fossas, Pamela" uniqKey="Garciadiego Fossas P" first="Pamela" last="Garciadiego-Fossas">Pamela Garciadiego-Fossas</name><name sortKey="Rojas Marin, Enrique" sort="Rojas Marin, Enrique" uniqKey="Rojas Marin E" first="Enrique" last="Rojas-Marin">Enrique Rojas-Marin</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000430 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000430 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:28558783
|texte= Clinical characteristics, predictors of immune reconstitution inflammatory syndrome and long-term prognosis in patients with Kaposi sarcoma.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:28558783" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |